8-K: Sera Prognostics Reports Q2 2025 Results, Eyes Growth

Sera Prognostics announced its second quarter 2025 financial results, highlighting strategic commercialization efforts and upcoming pivotal study data publication.

Summary

• Reported second quarter 2025 revenue of $17,000, a decrease from $24,000 in the second quarter of 2024.
• Total operating expenses remained flat at $9.3 million compared to the same period in 2024.
• Net loss for the quarter improved to $8.0 million, down from $8.3 million in the prior year.
• Research and development expenses decreased by approximately 24% to $3.3 million, primarily due to the completion of the pivotal PRIME study.
• Selling, general and administrative expenses increased to $6.0 million from $4.9 million, reflecting investments in commercial activities and market awareness.
• Held approximately $108.5 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2025, expected to fund operations through 2028.
• Made ongoing progress in engaging Medicaid plans in targeted states, showing traction in two states with high premature birth rates and two with leading healthcare systems.
• On track to publish full results of the PRIME study this year, with additional data on health economic benefits and Medicaid cost-saving benefits to follow.
• Strengthened the leadership team with key appointments in commercial, market access, and investor relations roles.

Sentiment

Score: 6

Explanation: While revenue declined, the company improved its net loss and maintains a strong cash position expected to last through 2028. Strategic hires and the imminent publication of pivotal study results indicate a positive trajectory for future commercialization, offsetting current revenue weakness.

Positives

• Net loss improved to $8.0 million in Q2 2025 from $8.3 million in Q2 2024.
• Net loss per share improved to $(0.16) in Q2 2025 from $(0.25) in Q2 2024.
• Research and development expenses decreased by approximately 24% to $3.3 million due to the completion of the pivotal PRIME study.
• Strong cash, cash equivalents, and available-for-sale securities balance of approximately $108.5 million as of June 30, 2025.
• Cash reserves are expected to fund the company through significant adoption and commercial milestones until 2028.
• Ongoing progress in engaging Medicaid plans in targeted states, with notable traction in two states with above-average premature birth rates.
• Full study results of the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study are "in hand" and on track for publication this year, which is enabling increased traction with managed Medicaid and other organizations.
• Strengthened leadership team with key appointments in commercial, market access, and investor relations, signaling a focus on commercialization and market expansion.

Negatives

• Revenue for Q2 2025 decreased to $17,000 from $24,000 in Q2 2024.
• Selling, general and administrative expenses increased to $6.0 million from $4.9 million in the prior-year period.
• The company continues to operate at a net loss of $8.0 million for the quarter.

Risks

• Continued net losses, cash generation challenges, and the potential need to raise more capital.
• Revenues from the PreTRM Test currently represent substantially all company revenues.
• The need for broad scientific and market acceptance of the PreTRM Test.
• A concentrated number of material customers.
• Ability to introduce new products.
• Potential competition in the market.
• Reliance on proprietary biobank.
• Dependence on critical suppliers.
• Uncertainty in estimates of total addressable market opportunity and forecasts of market growth.
• Challenges in obtaining potential third-party payer coverage and reimbursement.
• Impact of new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates.
• Changes in FDA regulation of laboratory-developed tests.
• Maintaining intellectual property rights protecting tests and market position.

Future Outlook

Sera Prognostics anticipates an acceleration in commercial momentum driven by the full PRIME pivotal study results, which are expected to be published this year. The company plans to share additional compelling data on health economic benefits and Medicaid expected cost-saving benefits of the PreTRM Test. Current cash reserves are projected to fund operations through significant adoption and commercial milestones until 2028, supporting anticipated revenue growth as commercialization expands.

Management Comments

• We continue to build the foundation needed for the expected acceleration in commercial momentum now that our full PRIME pivotal study results are in hand, which is enabling engaged conversations and increased traction with managed Medicaid and other organizations.
• Furthermore, we plan to share additional compelling data and evidence showing that our PreTRM test can truly make a difference in addressing the impact of premature births while empowering doctors with actionable information to improve pregnancy outcomes and reduce healthcare costs.

Industry Context

Sera Prognostics operates in the maternal and neonatal health diagnostics sector, focusing on addressing the significant public health challenge of preterm birth. Preterm birth is identified as the leading cause of illness and death in newborns, incurring substantial healthcare costs, estimated at approximately $25 billion annually in the United States for 2016. The company's PreTRM Test is positioned as the only broadly validated, commercially available blood-based biomarker test for early, individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies, aiming to provide physicians with actionable information to improve outcomes and reduce costs.

Management Changes

Stakeholder Impact

• Shareholders: Potential for future value creation through commercialization efforts and leveraging PRIME study results, but current revenue decline and ongoing losses present near-term challenges. Strong cash runway provides stability.
• Patients: Improved access to the PreTRM Test through Medicaid engagement, potentially leading to better pregnancy outcomes and reduced healthcare costs for those at risk of premature birth.
• Doctors/Healthcare Providers: Empowered with actionable information from the PreTRM Test to make more informed, personalized clinical decisions for women at increased risk of preterm birth.
• Medicaid Plans/Payers: Potential for significant cost savings in managing shortand long-term complications of prematurity through the adoption of the PreTRM Test.
• Employees: Strategic headcount additions and focus on commercialization suggest growth opportunities and stability, supported by a long cash runway.

Next Steps

• Publish full study results of the PRIME study this year.
• Publish additional data on health economic benefits, sub-population analysis, and Medicaid expected cost-saving benefits of the PreTRM Test following PRIME study publication.
• Continue engaging Medicaid plans and other organizations to accelerate commercial momentum.
• Host a conference call and live webcast on August 6, 2025, at 5:00 p.m. Eastern Time to discuss Q2 2025 results.

Key Dates

Recommendation

While Q2 2025 revenue declined, the company reported an improved net loss and maintains a robust cash position of $108.5 million, projected to fund operations through 2028. Strategic leadership appointments and the imminent publication of pivotal PRIME study results, which are already 'in hand,' are strong catalysts for future commercial momentum and potential revenue acceleration. The current financial performance reflects a transitional period as the company shifts from R&D to commercialization. Investors should hold to observe the impact of the PRIME study publication and the effectiveness of new commercial strategies on revenue growth and market adoption.

Keywords

Sera Prognostics, SERA, Q2 2025 Earnings, Financial Results, PreTRM Test, Premature Birth, Maternal Health, Neonatal Health, Biomarker, Diagnostics, Medicaid, PRIME Study, Healthcare Costs, Investor Relations, Market Access